ImmunityBio, Soon-Shiong Sued by Investor Over FDA Admonition

March 27, 2026, 7:56 PM UTC

ImmunityBio Inc. and its billionaire executive chairman Patrick Soon-Shiong overhyped its bladder cancer drug on former White House spokesman Sean Spicer’s podcast, an investor’s proposed class action said.

The complaint, filed Thursday in the US District Court for the Central District of California, centers around a US Food and Drug Administration warning letter about these and other comments issued to ImmunityBio and Soon-Shiong.

The letter publicized this week targeted Soon-Shiong’s claim that the drug, Anktiva, could treat “all cancers” and other statements on a January episode of The Sean Spicer Show. The FDA said these comments and a TV ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.